- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05397600
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
March 19, 2024 updated by: Laboratoires Thea
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
684
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barranquilla, Colombia, 80001
- Clínica Oftalmológica del Caribe
-
Bogotá, Colombia, 110231
- Fundación Oftalmológica Nacional (FUNDONAL)
-
Cali, Colombia, 760001
- Clinica de Oftalmologia de Cali SA
-
Floridablanca, Colombia, 681004
- Fundación Oftalmológica de Santander FOSCAL
-
Medellin, Colombia, 50024
- Instituto Nacional de Investigacion en Oftalmologia
-
Medellín, Colombia, 50021
- Clinica de Oftalmologia Sandiego
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Scheie Eye Institute
-
-
Texas
-
El Paso, Texas, United States, 79902
- Southwest Eye Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Informed consent dated and signed.
- Both eyes diagnosed open-angle glaucoma or ocular hypertension
Exclusion Criteria:
- History of trauma, infection, clinically significant inflammation within the previous 3 months
- Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
- Pregnancy or breast-feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T4032
|
Eyedrops
|
Active Comparator: Lumigan
|
Eyedrops
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline (Day 1) to Week 2, Week 6, and Week 12 in IOP.
Time Frame: up to Week12
|
Change from baseline (Day 1) to Week 2, Week 6, and Week 12 in IOP at three time points (8:00 a.m.; 10:00 a.m.; 4:00 p.m.) in the study eye.
|
up to Week12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 22, 2022
Primary Completion (Actual)
March 7, 2024
Study Completion (Actual)
March 7, 2024
Study Registration Dates
First Submitted
May 25, 2022
First Submitted That Met QC Criteria
May 27, 2022
First Posted (Actual)
May 31, 2022
Study Record Updates
Last Update Posted (Actual)
March 20, 2024
Last Update Submitted That Met QC Criteria
March 19, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT4032-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
Santen Inc.Completed
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Bimatoprost Ophthalmic
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedEyelash HypotrichosisUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
Salus UniversityNot yet recruitingNormal Tension GlaucomaUnited States
-
Amneal Pharmaceuticals, LLCCBCC Global Inc.; Amneal EU, LimitedNot yet recruitingOcular Hypertension | Open-angle GlaucomaUnited States
-
Amneal Pharmaceuticals, LLCCBCC Global ResearchRecruitingOcular Hypertension | Glaucoma, Open-AngleUnited States
-
Mankind Pharma LimitedCBCC Global ResearchCompleted
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedHypotrichosisUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawn